|Videos|October 11, 2021
GenesisCare physicians discuss PSMA-PET imaging agent Pylarify
Advertisement
GenesisCare doctors Kishore K. Dass, MD, Anurag Agarwal, MD, and Jerry Singer, MD, share their expert insight on the novel PSMA-PET imaging diagnostic Pylarify (piflufolastat F 18), which is FDA approved for use in patients with prostate cancer. The first US patient to receive Pylarify was treated at the GenesisCare facility in Boca Raton, Florida, where these doctors work.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Individualizing androgen pathway therapy in mCSPC
3
BOND-003 Cohort C: Efficacy Results
4
Laura Bukavina, MD, and Gabriela Díaz, MD, on the rise of young-onset bladder cancer
5




